Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to $1.0 million.

  • Dare Bioscience's Other Non-Current Assets rose 8702.94% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 8702.94%. This contributed to the annual value of $1.1 million for FY2024, which is 454.53% down from last year.
  • Per Dare Bioscience's latest filing, its Other Non-Current Assets stood at $1.0 million for Q3 2025, which was up 8702.94% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Dare Bioscience's Other Non-Current Assets registered a high of $1.8 million during Q3 2023, and its lowest value of $254295.0 during Q4 2022.
  • Over the past 5 years, Dare Bioscience's median Other Non-Current Assets value was $887858.0 (recorded in 2021), while the average stood at $894854.5.
  • Per our database at Business Quant, Dare Bioscience's Other Non-Current Assets surged by 35753.04% in 2023 and then tumbled by 6912.36% in 2024.
  • Dare Bioscience's Other Non-Current Assets (Quarter) stood at $485120.0 in 2021, then crashed by 47.58% to $254295.0 in 2022, then soared by 357.53% to $1.2 million in 2023, then fell by 4.55% to $1.1 million in 2024, then dropped by 8.3% to $1.0 million in 2025.
  • Its Other Non-Current Assets stands at $1.0 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.1 million for Q1 2025.